Trandolapril 4 mg Tablet Under Non-Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT00840073
First received: February 6, 2009
Last updated: July 6, 2009
Last verified: July 2009

February 6, 2009
July 6, 2009
October 2004
November 2004   (final data collection date for primary outcome measure)
  • Cmax - Maximum Observed Concentration [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-Inf - Area Under the Concentration-Time Curve From Time Zero to Infinity (Extrapolated) [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-t - Area Under the Concentration-Time Curve From Time Zero to Time of Last Non-Zero Concentration (Per Participant) [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
Bioequivalence based on Cmax and AUC [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00840073 on ClinicalTrials.gov Archive Site
  • Cmax - Trandolaprilat [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
  • AUC0-72 - Trandolaprilat [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Trandolapril 4 mg Tablet Under Non-Fasting Conditions
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Trandolapril 4 mg Tablets Under Fed Conditions.

The objective of this study is to evaluate the comparative bioavailability between trandolapril 4 mg tablets (test) and Mavik® 4 mg Tablets (reference) after a single-dose in healthy subjects under fed conditions.

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Trandolapril 4 mg Tablets
    1 x 4 mg, single-dose fed
  • Drug: Mavik® 4 mg Tablets
    1 x 4 mg, single-dose fed
  • Experimental: Trandolapril
    Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
    Intervention: Drug: Trandolapril 4 mg Tablets
  • Active Comparator: Mavik®
    Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
    Intervention: Drug: Mavik® 4 mg Tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
November 2004
November 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy, non-smoking, male and female subjects, 18 years of age or older.
  • BMI greater than or equal to 19 and less than or equal to 30.
  • Negative for HIV, Hepatitis B surface antigen and Hepatitis C antibody, urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone), urine cotinine test, serum HCG consistent with pregnancy (females only).
  • No significant diseases or clinically significant findings in a physical examination.
  • No clinically significant abnormal laboratory values.
  • No clinically significant findings in the 12-lead electrocardiogram (ECG).
  • Blood pressure over 90/60 mmHg and less than 140/90 mmHg.
  • Be informed of the nature of the study and given written consent prior to receiving any study procedure.
  • Females who are surgically sterile for at least six months or postmenopausal for at least one year, or who will avoid pregnancy prior to the study, during the study and up to one month after the end of the study.
  • Females who participate in this study are not pregnant and/or non-lactating.

Exclusion Criteria:

  • Known history or presence of any clinically significant medical condition.
  • Known history of food allergies, or any condition know to interfere with the absorption, distribution, metabolism or excretion of drugs.
  • Known or suspected carcinoma.
  • Presence or history of angioedema.
  • Known history or presence of hypersensitivity or idiosyncratic reaction to trandolapril and/or any other drug substances with similar activity; alcoholism within the last 12 months; drug dependence and/or substance abuse; use of tobacco or nicotine-containing products, within the last 6 months.
  • Any clinically significant illness or surgery within 4 weeks prior to drug administration.
  • On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
  • Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
  • Donated up to 250 mL of blood within the previous 30 days OR donated from 251 to 500 mL of blood in the previous 45 days OR donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation).
  • Use of any prescription medication within 14 days prior to period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to period 1 dosing (except spermicidal/barrier contraceptive products).
  • Use of any drug known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoine, glucocorticoids, omeprazole; examples of inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to period 1 dosing.
  • Females taking oral or transdermal hormonal contraceptives within 30 days preceding period 1 dosing OR Females having taken implanted or injected hormonal contraceptives (Depo-Provera) within one year prior to period 1 dosing.
  • Difficulty fasting or consuming the standard meals.
  • Do not tolerate venipuncture.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00840073
2004-842
No
Not Provided
Teva Pharmaceuticals USA
Not Provided
Principal Investigator: Xueyu (Eric) Chen, M.D., Ph. D. Pharma Medica
Teva Pharmaceuticals USA
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP